Managed Care

 

Ulcerative Colitis: The Value of Persistence in Therapy

Ulcerative Colitis: The Value of Persistence in Therapy

This Brief reviews a potential treatment option for patients with ulcerative colitis. This chronic inflammatory disease may significantly affect a person’s health and quality of life. A once-daily oral medication, MMX mesalamine, may be beneficial to these patients by limiting pill burden and potentially increasingly the likelihood of medication compliance.

Highlights:

  • Discussion of the incidence and prevalence of ulcerative colitis, along with its socioeconomic impact
  • Overview of the available treatment modalities, with a focus on 5-aminosalicylate therapy
  • Review of two pivotal trials that examined the efficacy of MMX mesalamine for patients with mild-to-moderative ulcerative colitis

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015